|View printer-friendly version|
|HeartWare Schedules Third Quarter Conference Call and Webcast|
FRAMINGHAM, Mass. and SYDNEY, Oct. 21, 2011 /PRNewswire via COMTEX/ --
HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three and nine months ended September 30, 2011, at 8:00 am U.S. Eastern Daylight Time on Friday, October 28, 2011 (being 11:00 pm Australian Eastern Daylight Time, Friday, October 28, 2011). The Company plans to release the financial results prior to the conference call.
The conference call with management will discuss the Company's financial results, highlights from the quarter and business outlook. The call may be accessed by dialing 1-877-941-2068 five minutes prior to the scheduled start time and referencing "HeartWare." For callers outside the U.S., please dial +1-480-629-9712.
A live webcast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Third Quarter 2011 Conference Call" under the section titled "Corporate Presentations" on the Home Page. A replay of the conference call will be available through the above weblink immediately following completion of the call.
A copy of the news release announcing results and related information will be available on the Company's web site, www.heartware.com.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® Pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia. The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant under a continued access protocol and destination therapy. For additional information, please visit www.heartware.com.
HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.
For further information:
SOURCE HeartWare International, Inc.